PLATELET-RICH PLASMA IMPROVES WOUND HEALING IN MULTIPLE MYELOMA BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW PATIENTS

被引：0

作者：

Coviello, V. ^{[1
]}

Peluso, F. ^{[2
]}

Dehkhargani, S. Z. ^{[1
]}

Verdugo, F. ^{[3
]}

Raffaelli, L. ^{[1
]}

Manicone, P. F. ^{[1
]}

D'Addona, A. ^{[1
]}

机构：

[1] Catholic Univ, Dept Oral Sci, Rome, Italy

[2] AORN St Anna & San Sebastiano, Dept Oral & Maxillofacial Surg & Odontostomatol, Caserta, Italy

[3] VA Hosp, Los Angeles, CA USA

来源：

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2012年 / 26卷 / 01期

关键词：

bisphosphonates; osteonecrosis of the jaw; multiple myeloma; platelet-rich plasma; RISK-FACTORS; AVASCULAR OSTEONECROSIS; CANCER-PATIENTS; PAMIDRONATE; NECROSIS; ZOLEDRONATE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bisphosphonates are drugs used to treat various metabolic and malignant bone diseases. In the past 10 years intravenous bisphosphonates have been associated with increased risk of osteonecrosis of the jaw (ONJ). The aim of the present study is to evaluate platelet-rich plasma (PRP) wound healing benefits in multiple myeloma (MM) patients who developed ONJ after surgical tooth extraction. The study included 7 patients, 2 males and 5 females. All individuals had been taking zoledronate or pamidronate followed by zoledronate for an average of 5 years. Four subjects had only standard surgical debridement and sequestrectomy to treat the ONJ and three had additional autologous PRP. The patients were followed-up for 3 months. The use of PRP to enhance wound healing and reduce bone exposure seems to be a good treatment protocol in ONJ MM subjects.

引用

页码：151 / 155

页数：5

共 20 条

[1] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
Badros, A
Weikel, D
Salama, A
Goloubeva, O
Schneider, A
Rapoport, A
Fenton, R
Gahres, N
Sausville, E
Ord, R
Meiller, T
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 945 - 952
[2] Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid
Cetiner, Sedat
Sucak, Gulsan Turkoz
Kahraman, Sevil Altundag
Aki, Sahika Zeynep
Kocakahyaoglu, Benay
Gultekin, Sibel Elif
Cetiner, Mustafa
Haznedar, Rauf
[J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (04) : 435 - 443
[3] Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma:: Report of 3 cases
Curi, Marcos Martins
Cossolin, Giuliano Saraceni Issa
Koga, Daniel Henrique
Araujo, Sergio Rocha
Feher, Olavo
dos Santos, Marcelo Oliveira
Zardetto, Cristina
[J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (02) : 349 - 355
[4] Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022
[5] Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
[6] A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
Jadu, F.
Lee, L.
Pharoah, M.
Reece, D.
Wang, L.
[J]. ANNALS OF ONCOLOGY, 2007, 18 (12) : 2015 - 2019
[7] Lee Cameron Y S, 2007, J Oral Implantol, V33, P371, DOI 10.1563/1548-1336(2007)33[371:UOPPIT]2.0.CO
[8] 2
[9] Platelet-rich plasma: Evidence to support its use
Marx, RE
[J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (04) : 489 - 496
[10] Platelet-rich plasma - Growth factor enhancement for bone grafts
Marx, RE
Carlson, ER
Eichstaedt, RM
Schimmele, SR
Strauss, JE
Georgeff, KR
[J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1998, 85 (06): : 638 - 646

← 1 2 →